{"slug":"ophthalmology","as_of":"2026-10-22","verified_at":"2026-10-22","languages":{"zh":{"title":"台灣眼科新藥公司與管線總表","summary":[{"text":"截至2026年10月22日，本表收錄3家台灣公司的眼科藥物或外泌體新藥管線。","source_urls":["https://www.formosapharma.com/pipeline-2/","https://mopsov.twse.com.tw/nas/STR/688520260922M001.pdf","https://www.bionettx.com/development-pipeline/"]},{"text":"所選APP13007已在美國上市，BRM411為台灣第2b期進行中，ExoTear仍在臨床前。","source_urls":["https://www.formosapharma.com/pipeline-2/","https://mopsov.twse.com.tw/nas/STR/688520260922M001.pdf","https://www.bionettx.com/development-pipeline/"]}],"undisclosed":"本表是核對來源後的公司與所選管線名單，並非完整產業清冊。階段依逐列來源日期描述，未公開的品名、適應症與事件日期不填補。"},"en":{"title":"Taiwan Ophthalmology Drug Companies and Pipelines","summary":[{"text":"As of October 22, 2026, this table includes ophthalmic drug or exosome programs at 3 Taiwan companies.","source_urls":["https://www.formosapharma.com/pipeline-2/","https://mopsov.twse.com.tw/nas/STR/688520260922M001.pdf","https://www.bionettx.com/development-pipeline/"]},{"text":"The selected APP13007 is launched in the U.S., BRM411 is in an ongoing Taiwan Phase 2b trial, and ExoTear remains preclinical.","source_urls":["https://www.formosapharma.com/pipeline-2/","https://mopsov.twse.com.tw/nas/STR/688520260922M001.pdf","https://www.bionettx.com/development-pipeline/"]}],"undisclosed":"This is a source-verified selection rather than an industry census. Stages retain their individual source dates; undisclosed names, indications and event dates are not filled in."}},"companies":[{"company":"台新藥","company_en":"Formosa Pharmaceuticals","ticker":"6838","product":"APP13007","product_en":"APP13007","indication":"眼科手術後發炎與疼痛","indication_en":"Inflammation and pain following ocular surgery","stage":"美國已核准並上市；加拿大已核准","stage_en":"U.S. approved and launched; approved in Canada","as_of":"2026-10-22","source":"https://www.formosapharma.com/pipeline-2/","quote":"Successfully obtained US FDA approval","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"台新藥股份有限公司","catalyst":null,"date_basis":"無日期現行管線頁，as_of為本次查閱日。"},{"company":"全福生技","company_en":"BRIM Biotechnology","ticker":"6885","product":"BRM411","product_en":"BRM411","indication":"青光眼","indication_en":"Glaucoma","stage":"台灣第2b期試驗進行中","stage_en":"Taiwan Phase 2b ongoing","as_of":"2026-09-22","source":"https://mopsov.twse.com.tw/nas/STR/688520260922M001.pdf","quote":"BRM411","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"全福生物科技股份有限公司","catalyst":{"text":"公司於2026年9月法說預計2027年第2季完成BRM411台灣第2b期，尚未核實完成。","text_en":"The September 2026 presentation planned Taiwan Phase 2b completion in Q2 2027; completion is not verified.","as_of":"2026-09-22","source":"https://mopsov.twse.com.tw/nas/STR/688520260922M001.pdf","quote":"BRM411"},"source_page":4,"date_basis":"封面明示2026年9月22日；第4頁圖片顯示台灣P2b試驗進行中，已視覺核對，原PDF第8頁亦有可抽取產品文字。"},{"company":"訊聯智藥","company_en":"BIONET Therapeutics","ticker":"7808","product":"ExoTear（幹細胞來源外泌體）","product_en":"ExoTear (stem-cell-derived exosomes)","indication":"乾眼症","indication_en":"Dry eye disease","stage":"臨床前","stage_en":"Preclinical","as_of":"2026-10-22","source":"https://www.bionettx.com/development-pipeline/","quote":"ExoTear","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R","company_quote":"訊聯細胞智藥股份有限公司","catalyst":null,"date_basis":"現行公司管線表；頁面顯示修改時間2026-09-20，as_of採本次查閱日。"}],"scope":{"not_exhaustive":true,"coverage":"Verified selection from the same read-only company-profile and pipeline inputs used in 0b04, because deploy/engine/src/data does not contain the original company profiles. One program selected per company.","stage_basis":"Stages reflect the cited source and its stated date. An undated live page uses the access date; source review does not make an old status a newly reported event.","count_basis":"Company rows, not independent assets or an industry-wide census. Parent-group, therapeutic-vaccine and planned regulatory-pathway roles are identified in each row."}}